CTLA4 and neoplasm: Using an immunoreactive transgenic mouse model with spontaneous HNSCC, Yu et al. found that targeting CTLA4 in the tumor microenvironment reduced myeloid-derived suppressor cells and macrophage levels and promoted T cell activation.